Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib

By Kalykaki Antonia   Agelaki Sofia   Kallergi Galatea   Xyrafas Alexandros   Mavroudis Dimitris   Georgoulias Vassilis  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 685-693

Springer Publishing Company

Access to resources Recommend Favorite

AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib

By Maiello Monica   D’Alessio Amelia   Luca Antonella   Carotenuto Adele   Rachiglio Anna   Napolitano Maria   Cito Letizia   Guzzo Antonella   Normanno Nicola  

Breast Cancer Research and Treatment, Vol. 102, Iss. 3, 2007-05 ,pp. : 275-282

Springer Publishing Company

Access to resources Recommend Favorite

Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib

By  

Oncology Reports, Vol. 33, Iss. 2, 2015-01 ,pp. : 526-532

Spandidos Publications

Access to resources Recommend Favorite

Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1

By        

Oncology Reports, Vol. 34, Iss. 2, 2015-01 ,pp. : 884-890

Spandidos Publications

Access to resources Recommend Favorite

Growth and EGFR Regulation in Breast Cancer Cells by Vitamin D and Retinoid Compounds

By McGaffin Kenneth   Acktinson Lisa   Chrysogelos Susan  

Breast Cancer Research and Treatment, Vol. 86, Iss. 1, 2004-07 ,pp. : 55-73

Springer Publishing Company

Access to resources Recommend Favorite